Inflammasomes: novel therapeutic targets for metabolic syndrome?
Chronic inflammation is a hallmark for Metabolic Syndrome (MetS). It is also one of the most important risk factors for insulin resistance and metabolic disorders. Inflammasomes, which are intracellular multiprotein complexes within the innate immune system, regulate the production and maturation of...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1569579/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849313306329743360 |
|---|---|
| author | Pengyu Cao Pengyu Cao Yulin Yang Yulin Yang Ningning Zhang Bojian Wang Zhenwei Gong |
| author_facet | Pengyu Cao Pengyu Cao Yulin Yang Yulin Yang Ningning Zhang Bojian Wang Zhenwei Gong |
| author_sort | Pengyu Cao |
| collection | DOAJ |
| description | Chronic inflammation is a hallmark for Metabolic Syndrome (MetS). It is also one of the most important risk factors for insulin resistance and metabolic disorders. Inflammasomes, which are intracellular multiprotein complexes within the innate immune system, regulate the production and maturation of pro-inflammatory cytokines including interleukin-1β (IL-1β) and IL-18 upon sensing pathogens or danger signals in the cytosol. A growing body of evidence indicates that inflammasomes play a pivotal role in the pathophysiology and progression of metabolic diseases, as deficiency in the key component of inflammasomes protects mice from high fat diet induced obesity and insulin resistance. Thus, in this review, we will summarize the role of inflammasomes in MetS and how to treat MetS by targeting inflammasomes. This may provide novel insights and therapeutic targets for treating metabolic disorders. |
| format | Article |
| id | doaj-art-94e4c2ff4a934bacb1bdfb3cd3dfc063 |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-94e4c2ff4a934bacb1bdfb3cd3dfc0632025-08-20T03:52:48ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-05-011610.3389/fendo.2025.15695791569579Inflammasomes: novel therapeutic targets for metabolic syndrome?Pengyu Cao0Pengyu Cao1Yulin Yang2Yulin Yang3Ningning Zhang4Bojian Wang5Zhenwei Gong6The Second People’s Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, ChinaChangzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, ChinaThe Second People’s Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, ChinaChangzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, ChinaThe Second People’s Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, ChinaSchool of Nursing, Jilin University, Changchun, Jilin, ChinaDivision of Endocrinology, Department of Pediatrics, Children’s Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA, United StatesChronic inflammation is a hallmark for Metabolic Syndrome (MetS). It is also one of the most important risk factors for insulin resistance and metabolic disorders. Inflammasomes, which are intracellular multiprotein complexes within the innate immune system, regulate the production and maturation of pro-inflammatory cytokines including interleukin-1β (IL-1β) and IL-18 upon sensing pathogens or danger signals in the cytosol. A growing body of evidence indicates that inflammasomes play a pivotal role in the pathophysiology and progression of metabolic diseases, as deficiency in the key component of inflammasomes protects mice from high fat diet induced obesity and insulin resistance. Thus, in this review, we will summarize the role of inflammasomes in MetS and how to treat MetS by targeting inflammasomes. This may provide novel insights and therapeutic targets for treating metabolic disorders.https://www.frontiersin.org/articles/10.3389/fendo.2025.1569579/fullobesitydiabetesdyslipidemiainflammationinnate immunityinterleukins |
| spellingShingle | Pengyu Cao Pengyu Cao Yulin Yang Yulin Yang Ningning Zhang Bojian Wang Zhenwei Gong Inflammasomes: novel therapeutic targets for metabolic syndrome? Frontiers in Endocrinology obesity diabetes dyslipidemia inflammation innate immunity interleukins |
| title | Inflammasomes: novel therapeutic targets for metabolic syndrome? |
| title_full | Inflammasomes: novel therapeutic targets for metabolic syndrome? |
| title_fullStr | Inflammasomes: novel therapeutic targets for metabolic syndrome? |
| title_full_unstemmed | Inflammasomes: novel therapeutic targets for metabolic syndrome? |
| title_short | Inflammasomes: novel therapeutic targets for metabolic syndrome? |
| title_sort | inflammasomes novel therapeutic targets for metabolic syndrome |
| topic | obesity diabetes dyslipidemia inflammation innate immunity interleukins |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2025.1569579/full |
| work_keys_str_mv | AT pengyucao inflammasomesnoveltherapeutictargetsformetabolicsyndrome AT pengyucao inflammasomesnoveltherapeutictargetsformetabolicsyndrome AT yulinyang inflammasomesnoveltherapeutictargetsformetabolicsyndrome AT yulinyang inflammasomesnoveltherapeutictargetsformetabolicsyndrome AT ningningzhang inflammasomesnoveltherapeutictargetsformetabolicsyndrome AT bojianwang inflammasomesnoveltherapeutictargetsformetabolicsyndrome AT zhenweigong inflammasomesnoveltherapeutictargetsformetabolicsyndrome |